FDA sued over antibiotic warnings

Share this article:

Public Citizen has filed a federal court suit asking that the FDA be forced to act on a petition the group says has been unanswered for 16 months, seeking a black-box warning on fluoroquinolone antibiotics (e.g., Cipro, Levaquin, and others) on the risk of serious tendon injury associated with the drug's use.

Public Citizen says the FDA has failed to act on its petition despite “long-standing evidence that fluoroquinolone antibiotics can cause tendon ruptures.”

It says a black-box warning would help make doctors and patients more aware of the risk before tendons actually rupture. The petition also asked the FDA to send a warning letter to physicians and to require an FDA-approved medication guide to be dispensed with prescriptions.

“While FDA sits idly by and ignores the problem, more people will suffer serious tendon ruptures that could have been prevented,” says Public Citizen Health Research Group director Sidney Wolfe. “The current warning is buried in a long list of possible adverse reactions and is far too easy to miss.”

Public Citizen reports that from November 1997 to December 2005, the FDA received 262 reports of tendon ruptures, mainly of the Achilles tendon; 258 cases of tendonitis; and 274 cases of other tendon disorders in patients using fluoroquinolone antibiotics. An additional 74 tendon ruptures, it says, have subsequently been reported to the FDA, for a total of 336. 
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.